The FDA on January 14, 2021 approved XALKORI® for pediatric patients 1 year of age and older and young adults with Relapsed or Refractory, systemic Anaplastic Large Cell Lymphoma (ALCL) that is ALK-positive. The safety and efficacy of XALKORI® have not been established in older adults with Relapsed or Refractory, systemic ALK-positive ALCL. XALKORI® is a product of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
